• 05.22.2018  |  UK Government and Bill & Melinda Gates Foundation join CARB-X partnership in fight against superbugs

    The UK Government’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) and the Bill & Melinda Gates Foundation (BMGF) have joined the CARB-X partnership to support scientific research around the world to develop new vaccines, preventatives, and other products against drug-resistant bacterial infections, particularly among vulnerable populations in low- and middle-income countries.

    Full Story

  • 05.15.2018  |  CARB-X funds MicrobeDx to support development of a transformative testing system to rapidly diagnose life-threatening infections in the urinary tract

    MicrobeDx’s system could diagnose infections and identify the bug causing it within 30 minutes, and tell doctors within three hours which antibiotic to prescribe to kill the bacteria

    Full Story

  • 05.10.2018  |  CARB-X funds Talis Biomedical to develop systems to diagnose chlamydia and gonorrhea within minutes and determine which antibiotics would kill the bacteria

    CARB-X is awarding Talis Biomedical Corporation of Menlo Park, CA, up to $4.4 million, with the possibility of up to $4.2 million more based on achievement of project milestones, to support the development of the company's molecular diagnostic system which would speed diagnosis and appropriate treatment of chlamydia and gonorrhea, including drug-resistant infections.

    Full Story

  • 05.07.2018  |  CARB-X partners with Melinta Therapeutics to accelerate the development of a new class of antibiotic to battle multiple life-threatening superbugs

    CARB-X is teaming up with Melinta Therapeutics (NASDAQ: MLNT) to support the development of a new class of antibiotic called pyrrolocytosine to treat the most serious drug-resistant bacterial infections.

    Full Story

  • 04.26.2018  |  CARB-X announces award to Achaogen to advance the development of next-generation aminoglycoside antibiotic to treat highly-resistant gram-negative pathogens

    CARB-X is funding Achaogen, Inc. (NASDAQ: AKAO) of South San Francisco, CA, to support the development of a next-generation broad-spectrum aminoglycoside antibiotic capable of overcoming resistance mechanisms and potentially treating highly-resistant pathogens such as Pseudomonas aeruginosa and Acinetobacter baumannii.

    Full Story